NCT07408609
Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Eligibility criteria expanded, about 2 words
- Start date changed from estimate of Feb 26, 2026 to May 14, 2026
- Secondary endpoints: details revised at 4 of 4 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Pathological Complete Response (pCR) Rate (ITT Population)
Timeframe: At the time of surgery following completion of neoadjuvant therapy, based on pathological evaluation of the resected surgical specimen.
Secondary (4)
Pathological Complete Response (pCR) Rate (Surgical Population)
R0 Resection Rate
Event-Free Survival (EFS)
Overall Survival (OS)
Arms and interventions
Chemotherapy combined with TislelizumabExperimental
ChemotherapyActive comparator
Drugs: Low Dose Radiotherapy Combined with Tislelizumab and Chemotherapy, Chemotherapeutic Agent
Devices: low-dose radiotherapy
Sites
1 site in 1 country
- Jiangsu Cancer Institute & HospitalNanjing, Jiangsu, China